 |
40 Diseases |  |
13 Trials |
|
13 Trials |  |
222 News |  |
| «123» |
- ||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment open: Efficacy and Safety of Oxycodone/Naloxone (Targin (clinicaltrials.gov) - Dec 19, 2018
P4, N=123, Recruiting, Sponsor: Mundipharma Korea Ltd
Active, not recruiting --> Recruiting
- |||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P4 trial: Efficacy and Safety of Oxycodone/Naloxone (Targin (clinicaltrials.gov) - Dec 6, 2018
P4, N=123, Active, not recruiting, Sponsor: Mundipharma Korea Ltd
- | oxycodone/naloxone ER / Generic mfg.
Trial initiation date: Targin (clinicaltrials.gov) - Nov 1, 2018
P3, N=20, Not yet recruiting, Sponsor: University of British Columbia
Active, not recruiting --> Recruiting Initiation date: Jun 2018 --> Dec 2018
- || oxycodone/naloxone ER / Generic mfg.
Trial initiation date: Targin (clinicaltrials.gov) - May 2, 2018
P3, N=20, Not yet recruiting, Sponsor: University of British Columbia
Initiation date: Jun 2018 --> Dec 2018 Initiation date: Jun 2017 --> Jun 2018
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion, Trial primary completion date: Targin for Non-cancer Pain (clinicaltrials.gov) - Nov 14, 2017
P3, N=230, Completed, Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd
Initiation date: Jun 2017 --> Jun 2018 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Mar 2017
- ||| oxycodone/naloxone ER / Generic mfg.
New P3 trial: Targin (clinicaltrials.gov) - Jun 7, 2017
P3, N=20, Not yet recruiting, Sponsor: University of British Columbia
- | oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion: Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia (clinicaltrials.gov) - Mar 7, 2017
P4, N=90, Completed, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Mar 2017 Recruiting --> Completed
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion: To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain (clinicaltrials.gov) - Nov 4, 2016
P2/3, N=155, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Recruiting --> Completed Active, not recruiting --> Completed
- |||| oxycodone/naloxone ER / Generic mfg.
Trial primary completion date: Targin for Non-cancer Pain (clinicaltrials.gov) - Mar 30, 2016
P3, N=230, Recruiting, Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Sep 2016
- duloxetine / Generic mfg.
Trial primary completion date: Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty? (clinicaltrials.gov) - Feb 21, 2016
P2, N=168, Recruiting, Sponsor: Hanyang University Seoul Hospital
Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| oxycodone/naloxone ER / Generic mfg.
Enrollment closed: To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain (clinicaltrials.gov) - Dec 14, 2015
P2/3, N=144, Active, not recruiting, Sponsor: Mundipharma Research GmbH & Co KG
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- |||| oxycodone/naloxone ER / Generic mfg.
Trial completion: A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects (clinicaltrials.gov) - Dec 14, 2015
P2, N=108, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- oxycodone/naloxone ER / Generic mfg.
Trial completion, Trial primary completion date, Surgery: TACS: A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery (clinicaltrials.gov) - Nov 15, 2015
P3, N=50, Completed, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2015 --> Aug 2015
- oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment open: Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia (clinicaltrials.gov) - Sep 14, 2015
P4, N=90, Recruiting, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | Trial primary completion date: May 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- |||| oxycodone/naloxone ER / Generic mfg.
Trial primary completion date: Targin for Non-cancer Pain (clinicaltrials.gov) - Aug 21, 2015
P3, N=270, Recruiting, Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> Jun 2016
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion, Trial primary completion date: Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain (clinicaltrials.gov) - Aug 18, 2015
P3, N=232, Completed, Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd
Trial primary completion date: May 2017 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Aug 2015
- | oxycodone/naloxone ER / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, HEOR: Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=37, Completed, Sponsor: Mundipharma AB
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Aug 2015 Recruiting --> Completed | N=200 --> 37 | Trial primary completion date: Mar 2014 --> Jun 2015
- | oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P4 trial: Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia (clinicaltrials.gov) - Aug 5, 2015
P4, N=90, Not yet recruiting, Sponsor: University Hospital Inselspital, Berne
- oxycodone/naloxone ER / Generic mfg.
Trial completion: An Interventional Study to Compare the Efficacy and Tolerability With Targin (clinicaltrials.gov) - Jul 9, 2015
P4, N=261, Completed, Sponsor: Mundipharma Korea Ltd
Recruiting --> Completed | N=200 --> 37 | Trial primary completion date: Mar 2014 --> Jun 2015 Active, not recruiting --> Completed
- oxycodone/naloxone ER / Generic mfg.
Trial completion, Phase classification, Enrollment change: PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain (clinicaltrials.gov) - Jul 9, 2015
P4, N=359, Completed, Sponsor: Mundipharma Korea Ltd
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: PN/A --> P4 | N=512 --> 359
- pregabalin / Generic mfg.
Trial completion, Enrollment change: A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) (clinicaltrials.gov) - Jul 9, 2015
P4, N=73, Completed, Sponsor: Mundipharma Korea Ltd
Recruiting --> Completed | Phase classification: PN/A --> P4 | N=512 --> 359 Recruiting --> Completed | N=119 --> 73
- oxycodone controlled release / Generic mfg.
Trial completion, Trial primary completion date: A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients (clinicaltrials.gov) - Jul 9, 2015
P4, N=128, Completed, Sponsor: Mundipharma Korea Ltd
Recruiting --> Completed | N=119 --> 73 Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Oct 2013
- oxycodone/naloxone ER / Generic mfg.
Trial completion: A Non-interventional, Observational Study for Targinact (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=68, Completed, Sponsor: Mundipharma CVA
Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Oct 2013 Active, not recruiting --> Completed
- |||||||||| oxycodone/naloxone ER / Generic mfg.
New P2/3 trial: To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain (clinicaltrials.gov) - Dec 22, 2014
P2/3, N=132, Recruiting, Sponsor: Mundipharma Research GmbH & Co KG
- | duloxetine / Generic mfg.
New P2 trial: Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty? (clinicaltrials.gov) - Dec 6, 2014
P2, N=168, Recruiting, Sponsor: Hanyang University Seoul Hospital
- oxycodone/naloxone ER / Generic mfg.
Enrollment open, Trial initiation date, Surgery: TACS: A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery (clinicaltrials.gov) - Dec 5, 2014
P3, N=50, Recruiting, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014
- ||| oxycodone/naloxone ER / Generic mfg.
Enrollment closed: A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects (clinicaltrials.gov) - Nov 18, 2014
P2, N=100, Active, not recruiting, Sponsor: Mundipharma Research GmbH & Co KG
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- ||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion, Enrollment change: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Nov 7, 2014
P3, N=450, Completed, Sponsor: Purdue Pharma LP
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=900 --> 450
- ||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion, Enrollment change: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - Nov 7, 2014
P3, N=455, Completed, Sponsor: Purdue Pharma LP
Active, not recruiting --> Completed | N=900 --> 450 Active, not recruiting --> Completed | N=600 --> 455
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion, Head-to-Head: A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy (clinicaltrials.gov) - Oct 17, 2014
P3, N=270, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Active, not recruiting --> Completed | N=600 --> 455 Active, not recruiting --> Completed
- ||||| oxycodone/naloxone ER / Generic mfg.
Enrollment change: Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Sep 4, 2014
P3, N=1095, Completed, Sponsor: Purdue Pharma LP
Active, not recruiting --> Completed N=600 --> 1095
- |||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial primary completion date: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Aug 4, 2014
P3, N=900, Active, not recruiting, Sponsor: Purdue Pharma LP
N=600 --> 1095 Trial primary completion date: Mar 2015 --> Oct 2014
- |||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial primary completion date: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - Aug 4, 2014
P3, N=600, Active, not recruiting, Sponsor: Purdue Pharma LP
Trial primary completion date: Mar 2015 --> Oct 2014 Trial primary completion date: Mar 2015 --> Oct 2014
- ||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment closed: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - May 15, 2014
P3, N=900, Active, not recruiting, Sponsor: Purdue Pharma LP
Trial primary completion date: Mar 2015 --> Oct 2014 Recruiting --> Active, not recruiting
- ||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment closed: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - May 15, 2014
P3, N=600, Active, not recruiting, Sponsor: Purdue Pharma LP
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- oxycodone/naloxone ER / Generic mfg.
New P3 trial, Surgery: TACS: A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery (clinicaltrials.gov) - Apr 8, 2014
P3, N=50, Not yet recruiting, Sponsor: University of Edinburgh
- ||| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
Enrollment change: Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component. (clinicaltrials.gov) - Apr 3, 2014
P4, N=367, Completed, Sponsor: Gr
Recruiting --> Active, not recruiting N=240 --> 367
- |||| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
Trial completion: Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component. (clinicaltrials.gov) - Apr 3, 2014
P4, N=367, Completed, Sponsor: Gr
N=240 --> 367 Recruiting --> Completed
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion: A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain (clinicaltrials.gov) - Feb 4, 2014
P3, N=172, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| oxycodone/naloxone ER / Generic mfg.
Enrollment closed, Head-to-Head: A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy (clinicaltrials.gov) - Jan 7, 2014
P3, N=270, Active, not recruiting, Sponsor: Mundipharma Research GmbH & Co KG
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| oxycodone/naloxone ER / Generic mfg.
Enrollment closed: An Interventional Study to Compare the Efficacy and Tolerability With Targin (clinicaltrials.gov) - Dec 8, 2013
P4, N=260, Active, not recruiting, Sponsor: Mundipharma Korea Ltd
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- oxycodone/naloxone ER / Generic mfg.
Enrollment change: A Non-interventional, Observational Study for Targinact (clinicaltrials.gov) - Nov 10, 2013
P=N/A, N=68, Active, not recruiting, Sponsor: Mundipharma CVA
Recruiting --> Active, not recruiting N=125 --> 68
- oxycodone/naloxone ER / Generic mfg.
Enrollment closed: A Non-interventional, Observational Study for Targinact (clinicaltrials.gov) - Nov 10, 2013
P=N/A, N=68, Active, not recruiting, Sponsor: Mundipharma CVA
N=125 --> 68 Recruiting --> Active, not recruiting
- oxycodone/naloxone ER / Generic mfg.
Trial completion: A Non-interventional, Observational Study for Targinact (clinicaltrials.gov) - Nov 5, 2013
P=N/A, N=1338, Completed, Sponsor: Mundipharma CVA
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- ||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment change: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - Oct 29, 2013
P3, N=600, Recruiting, Sponsor: Purdue Pharma LP
Not yet recruiting --> Completed N=900 --> 600
- |||||||||| oxycodone/naloxone ER / Generic mfg.
New P3 trial: A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain (clinicaltrials.gov) - Oct 27, 2013
P3, N=463, Completed, Sponsor: Mundipharma Research GmbH & Co KG
- |||||| oxycodone/naloxone ER / Generic mfg.
Enrollment open: Targin for Non-cancer Pain (clinicaltrials.gov) - Oct 7, 2013
P3, N=270, Recruiting, Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd
N=900 --> 600 Not yet recruiting --> Recruiting
- |||| oxycodone/naloxone ER / Generic mfg.
Enrollment open: A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects (clinicaltrials.gov) - Aug 11, 2013
P2, N=100, Recruiting, Sponsor: Mundipharma Research GmbH & Co KG
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| oxycodone/naloxone ER / Generic mfg.
New P3 trial: Targin for Non-cancer Pain (clinicaltrials.gov) - Aug 5, 2013
P3, N=270, Recruiting, Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd
- || Movicol (polyethylene glycol/sodium bicarbonate/sodium chloride/potassium chloride) / Mochida, Eisai, Norgine
New P2/3 trial, Adverse events: A new way of evaluating the adverse effects of opioids on the gut. En ny m (EUDRACT) - Jul 31, 2013
P2/3, N=70, Ongoing, Sponsor: Mech-Sense, Aalborg University Hospital